The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Millions of Americans rely on GLP-1 drugs to improve their health, but bad actors are peddling dangerous fakes.” ...

Mississippi Attorney General Lynn Fitch joined a bipartisan 37-state coalition requesting that the Food and Drug ...

The West Virginia Attorney General has joined a bipartisan coalition of 37 states and territories urging the Food and Drug Administration to act against produce ...

South Carolina Attorney General Alan Wilson led a 37-state coalition that wants the FDA to take action against manufacturers ...

A controversial Super Bowl ad by Hims & Hers targets America's obesity epidemic and criticizes the healthcare system. The ad ...

Denmark is home to Novo Nordisk NVO, the company behind Ozempic and Wegovy, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs ...

The popularity of semaglutide, the active ingredient in Ozempic and Wegovy, has skyrocketed in recent years. Those considering semaglutide for weight loss treatment may wonder about dosing and how ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...

Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...